Researchers from Broad Institute and Dana-Farber Cancer Institute have described a new method that dramatically simplifies an arduous experimental process in early drug discovery. Their method, called PRISM, uses a molecular barcoding system to test potential drug compounds on cancer and other cell lines at unprecedented scale and speed. The system allows for pooling and testing of multiple cell lines simultaneously, accelerating the search for targeted therapies and better representing the genetic diversity of disease.